![Diabetes Care Devices Market by Type [Diabetes Monitoring (CGM, Test Strips, Self-Monitoring Blood Glucose Meters, Lancets, Haemoglobin A1C Testing Kits)], [Insulin Delivery (Syringes, Pens, Pumps, Jet Injectors)] - Global Forecast to 2028- Product Image](http://www.researchandmarkets.com/product_images/12194/12194704_500px_jpg/diabetes_care_devices_market.jpg)
Diabetes Care Devices Market by Type [Diabetes Monitoring (CGM, Test Strips, Self-Monitoring Blood Glucose Meters, Lancets, Haemoglobin A1C Testing Kits)], [Insulin Delivery (Syringes, Pens, Pumps, Jet Injectors)] - Global Forecast to 2028
The Diabetes Care Devices Market is expected to grow at a CAGR of 6.7% from 2021 to reach $31.9 billion by 2028.
Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the diabetes care devices market is mainly attributed to increased adoption of test strips and self-monitoring blood glucose meters and increasing demand for continuous glucose monitoring with rising awareness towards the disease in developing countries.
The global diabetes care devices market is segmented based on type: (Diabetes Monitoring Devices and Insulin Delivery Devices) and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market share at a global level.
Based on type, the diabetes care devices market is segmented into diabetes monitoring devices and insulin delivery devices. In 2021, the diabetes monitoring devices segment is estimated to account for the largest share of the total diabetes care devices market. The growth of diabetes monitoring devices is attributed to the factors such as increased adoption of test strips and self-monitoring blood glucose meters and increasing demand for continuous glucose monitoring with rising awareness towards the disease in developing countries.
Geographically, in 2021, North America is estimated to account for the largest share of the global diabetes care devices market, followed by Europe and Asia-Pacific. Factors such as the increasing prevalence of diabetes with the rising need to self-monitor and treat the disease, increasing prevalence of major risk factors of diabetes such as obesity and sedentary lifestyle, increasing geriatric population, and growing government initiatives promoting diabetes care are driving the growth of the diabetes care devices market in North America. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period
An in-depth analysis of the geographical scenario of the diabetes care devices market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). In 2021, North America is estimated to account for the largest share of the global diabetes care devices market, followed by Europe and Asia-Pacific.
The key players operating in the global diabetes care devices market are Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), LifeScan IP Holdings, LLC (U.S.), Medtronic PLC (Ireland), Becton, Dickinson and Company (U.S.), Terumo Corporation (Japan), and Sanofi AS (France), Tandem Diabetes Care, Inc. (U.S.), Insulate Corporation (U.S.) and DexCom, Inc. (U.S.)
The Diabetes Care Devices Market is expected to grow at a CAGR of 6.7% from 2021 to reach $31.9 billion by 2028.
Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the diabetes care devices market is mainly attributed to increased adoption of test strips and self-monitoring blood glucose meters and increasing demand for continuous glucose monitoring with rising awareness towards the disease in developing countries.
The global diabetes care devices market is segmented based on type: (Diabetes Monitoring Devices and Insulin Delivery Devices) and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market share at a global level.
Based on type, the diabetes care devices market is segmented into diabetes monitoring devices and insulin delivery devices. In 2021, the diabetes monitoring devices segment is estimated to account for the largest share of the total diabetes care devices market. The growth of diabetes monitoring devices is attributed to the factors such as increased adoption of test strips and self-monitoring blood glucose meters and increasing demand for continuous glucose monitoring with rising awareness towards the disease in developing countries.
Geographically, in 2021, North America is estimated to account for the largest share of the global diabetes care devices market, followed by Europe and Asia-Pacific. Factors such as the increasing prevalence of diabetes with the rising need to self-monitor and treat the disease, increasing prevalence of major risk factors of diabetes such as obesity and sedentary lifestyle, increasing geriatric population, and growing government initiatives promoting diabetes care are driving the growth of the diabetes care devices market in North America. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period
An in-depth analysis of the geographical scenario of the diabetes care devices market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). In 2021, North America is estimated to account for the largest share of the global diabetes care devices market, followed by Europe and Asia-Pacific.
The key players operating in the global diabetes care devices market are Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), LifeScan IP Holdings, LLC (U.S.), Medtronic PLC (Ireland), Becton, Dickinson and Company (U.S.), Terumo Corporation (Japan), and Sanofi AS (France), Tandem Diabetes Care, Inc. (U.S.), Insulate Corporation (U.S.) and DexCom, Inc. (U.S.)
Scope of the Report:
Global Diabetes Care Devices Market, by Type
- Diabetes Monitoring Devices
- Insulin Delivery Devices
Global Diabetes Care Devices Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Global Diabetes Care Devices Market, by Type
6. Diabetes Care Devices Market, by Geography
6.3. Europe
7. Competitive Landscape
8. Company Profiles
9. Appendix
Companies Mentioned
- Novo Nordisk A/S
- Ypsomed AG
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- F. Hoffmann-La Roche Ltd
- LifeScan IP Holdings LLC
- Medtronic PLC
- Becton Dickinson and Company
- Terumo Corporation
- Sanofi AS
- Tandem Diabetes Care Inc.
- Insulate Corporation and DexCom Inc. .
